New drug shows promise in reversing dangerous liver scarring

NCT ID NCT05989711

Completed Disease control Sponsor: Altimmune, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether a weekly injection called pemvidutide could help people with a serious fatty liver disease called NASH. Researchers compared the drug to a placebo in 212 adults to see if it could reduce liver inflammation and scarring. The main goal was to see if the drug could resolve the disease or improve liver scarring after 24 weeks of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Altimmune Clinial Study Site

Tucson, Arizona, 85704, United States
Altimmune Clinical Study Site

Chandler, Arizona, 85224, United States
Altimmune Clinical Study Site

Peoria, Arizona, 85345, United States
Altimmune Clinical Study Site

Tucson, Arizona, 85701, United States
Altimmune Clinical Study Site

North Hollywood, California, 33019, United States
Altimmune Clinical Study Site

Panorama City, California, 91402, United States
Altimmune Clinical Study Site

Englewood, Colorado, 80110, United States
Altimmune Clinical Study Site

Bradenton, Florida, 34201, United States
Altimmune Clinical Study Site

Fort Myers, Florida, 33912, United States
Altimmune Clinical Study Site

Hialeah Gardens, Florida, 33018, United States
Altimmune Clinical Study Site

Miami Lakes, Florida, 33014, United States
Altimmune Clinical Study Site

Port Orange, Florida, 32123, United States
Altimmune Clinical Study Site

Sarasota, Florida, 34240, United States
Altimmune Clinical Study Site

West Palm Beach, Florida, 33401, United States
Altimmune Clinical Study Site

Dalton, Georgia, 30720, United States
Altimmune Clinical Study Site

Marietta, Georgia, 30006, United States
Altimmune Clinical Study Site

Bastrop, Louisiana, 78602, United States
Altimmune Clinical Study Site

Shreveport, Louisiana, 71101, United States
Altimmune Clinical Study Site

Clarksville, Tennessee, 37040, United States
Altimmune Clinical Study Site

Germantown, Tennessee, 38138, United States
Altimmune Clinical Study Site

Austin, Texas, 73301, United States
Altimmune Clinical Study Site

Bellaire, Texas, 77401, United States
Altimmune Clinical Study Site

Edinburg, Texas, 78539, United States
Altimmune Clinical Study Site

Edinburg, Texas, 78540, United States
Altimmune Clinical Study Site

Georgetown, Texas, 78626, United States
Altimmune Clinical Study Site

Houston, Texas, 77036, United States
Altimmune Clinical Study Site

San Antonio, Texas, 78201, United States
Altimmune Clinical Study Site

San Antonio, Texas, 78204, United States
Altimmune Clinical Study Site

West Jordan, Utah, 84081, United States
Altimmune Clinical Study Site

San Juan, 00901, Puerto Rico
Austin Health

Heidelberg, Victoria, 3084, Australia
Box Hill Hospital

Box Hill, Victory, 3128, Australia
Fiona Stanley Hospital

Murdoch, Western Australia, 6150, Australia
Flinders Medical Centre

Bedford Park, South Australia, 5042, Australia
Liverpool Hospital

Liverpool, New South Wales, 2170, Australia
Monash Hospital

Clayton, Victory, 3168, Australia
Princess Alexandra Hospital/ Translational Research Institute

Woolloongabba, Queensland, 4102, Australia
Royal Prince Alfred Hospital

Camperdown, New South Wales, 2050, Australia
Sir Charles Gairdner Hospital

Nedlands, Western Australia, 6009, Australia
St. Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065, Australia

Conditions

Explore the condition pages connected to this study.

NON-ALCOHOLIC STEATOHEPATITIS (NASH)